New combo therapy for diabetic dialysis patients shows promise
NCT ID NCT02176681
First seen Nov 01, 2025 · Last updated Jun 20, 2026 · Updated 41 times
Summary
This study tested whether adding vildagliptin (a diabetes pill) to insulin helps control blood sugar in people with type 2 diabetes who are on hemodialysis. 70 patients were randomly assigned to receive either insulin alone or insulin plus vildagliptin for 12 weeks. The goal was to see if the combination improved blood sugar levels and reduced dangerous lows (hypoglycemia).
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HAEMODIALYZED, TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AURAL Clinique Sainte Anne
Strasbourg, 67000, France
-
AURAL Colmar
Colmar, 68000, France
-
AURAL Mulhouse
Mulhouse, 68070, France
-
AURAL Strasbourg
Strasbourg, 67200, France
-
CH d'Amiens
Amiens, 80054, France
-
CH de Besançon
Besançon, 25030, France
-
CH de Dijon
Dijon, 21079, France
-
CH de Mulhouse
Mulhouse, 68070, France
-
CH de Nancy
Nancy, 54000, France
-
CH de Valenciennes
Valenciennes, 59300, France
-
Clinique Sainte Anne
Strasbourg, 67000, France
-
Hospices civils de Colmar
Colmar, 68024, France
-
Hôpitaux Universitaires de Strasbourg
Strasbourg, 67091, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Vildagliptin (Galvus) added to insulin
What this could lead to
If successful, this could provide a safe and effective way to improve blood sugar control in diabetic patients on dialysis, potentially reducing complications.
What could go wrong
This is a small, early-phase study (70 participants) that only lasted 12 weeks, so results may not apply to all patients. Adding a new drug also carries risks of side effects or interactions.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.